AUA 2017 Bladder Cancer
Viewing 41-60 of 73 articles
AUA 2017: What is the Best Imaging and What Will We Be Using in the Future: Cystoscopy and Cross-Sectional Imaging?
AUA 2017: Beyond Cytology: What is the Urinary Marker We Should Use Now and What Will Be the Best in the Future?
AUA 2017: Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): final results and translational findings of an open-label, single-arm, phase 2 study
AUA 2017: Development and external validation of a novel 12-gene signature on muscle-invasive bladder cancer for prediction of overall survival: linkage to data from The Cancer Genome Atlas
AUA 2017: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy
AUA 2017: Prognostic Value of PD-1 and PD-L1 Expression in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract
AUA 2017: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy: Development of a single sample patient assay
AUA 2017: High risk non-muscle invasive bladder cancer treated with sequential BCG/electromotive drug administration mitomycin C (EDMA-MMC): 2% disease-specific mortality at 4 years’ follow-up
AUA 2017: The Benefit of Continuous Saline Bladder Irrigation After Transurethral Resection in High-Grade Non-Muscle-Invasive Bladder Cancer: A Single-Center, Randomized, Prospective Study
AUA 2017: Immediate intravesical chemotherapy for low grade bladder tumors in California: an underutilized practice and its impact on recurrence
AUA 2017: Is there a role for upper tract urinary tract imaging surveillance in the follow-up of non-muscle invasive bladder cancer?
AUA 2017: Laparoscopic Versus Open Nephrectomy For Xanthogranulomatous Pyelonephritis: A Contemporary Series